{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:52:15Z","timestamp":1777909935414,"version":"3.51.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      The purpose of this study was to evaluate the potential of voclosporin (VOS) in preventing goblet cell (GC) loss and modulating interferon-gamma (IFN-\u03b3) producing CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells in the mouse desiccating stress (DS) dry eye model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Mice were subjected to DS and treated topically with vehicle, VOS, or cyclosporine A as a treatment control. Corneal barrier function was evaluated after 5 and conjunctival GC density after 10 days of desiccation. CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells were isolated from ocular surface draining lymph nodes of dry eye donor mice and adoptively transferred into immune deficient RAG1\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice from which tears and conjunctiva were collected for the evaluation of inflammatory cytokines\/chemokines and GC density.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compared to the vehicle-treated group, VOS was significantly better in preserving corneal barrier function and preventing DS-induced conjunctival GC loss. CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells from VOS treated dry eye donors caused less conjunctival GC loss than vehicle and suppressed expression of IFN-\u03b3 signature genes to a similar extent and transforming growth factor-beta to a greater extent than cyclosporine in adoptive transfer recipients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      These findings suggest that VOS preserves corneal barrier function and conjunctival GCs and suppresses IFN-\u03b3 producing CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells in experimental dry eye.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0005","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T17:48:49Z","timestamp":1595958529000},"page":"679-685","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Calcineurin Inhibitor Voclosporin Preserves Corneal Barrier and Conjunctival Goblet Cells in Experimental Dry Eye"],"prefix":"10.1177","volume":"36","author":[{"given":"Jehan","family":"Alam","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo G.","family":"de Souza","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Stern","sequence":"additional","affiliation":[{"name":"Immuneyez, Mission Viejo, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia S.","family":"de Paiva","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Pflugfelder","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, Texas, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000664"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy045"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.02.004"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18050978"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0069"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.86"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-7081"},{"key":"e_1_3_3_10_2","first-page":"CD010051","article-title":"Topical cyclosporine A therapy for dry eye syndrome","volume":"9","author":"de Paiva C.S.","year":"2019","unstructured":"de Paiva C.S., , Pflugfelder S.C., , Ng S.M., et al. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst. Rev. 9:CD010051, 2019.","journal-title":"Cochrane Database Syst. Rev"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.8.1046"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.7.5.24"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.330"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.08.013"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00192-2"},{"key":"e_1_3_3_16_2","first-page":"542","article-title":"ISAtx-247 (Isotechnika\/Roche)","volume":"5","author":"Dumont F.J.","year":"2004","unstructured":"Dumont F.J. ISAtx-247 (Isotechnika\/Roche). Curr. Opin. Investig. Drugs. 5:542\u2013550, 2004.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.10.1525"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.4137\/OED.S7995"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181757997"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.06.004"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.3950"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30037-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181cf98ff"},{"key":"e_1_3_3_24_2","first-page":"1646","article-title":"Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247","volume":"29","author":"Maksymowych W.P.","year":"2002","unstructured":"Maksymowych W.P., , Jhangri G.S., , Aspeslet L., et al. Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247. J. Rheumatol. 29:1646\u20131652, 2002.","journal-title":"J. Rheumatol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-1891"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000131950.75697.71"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.061"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.11.011"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2009.5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029017"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.03.014"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:43:57Z","timestamp":1777646637000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.1089\/jop.2020.0005"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0005","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}